ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
US grants AZ’ Fasenra orphan drug status for rare autoimmune disease
November 27, 2018US regulators have granted AstraZeneca’s Fasenra Orphan Drug Designation (ODD) for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare and potentially fatal autoimmune disease. -
US grants AZ’ Fasenra orphan drug status for rare autoimmune disease
November 27, 2018US regulators have granted AstraZeneca’s Fasenra Orphan Drug Designation (ODD) for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare and potentially fatal autoimmune disease.
Pharma Sources Insight January 2025
